New standard treatment for breast cancer at early stages established
December 4th, 2010 - 3:16 pm ICT by ANILondon, Dec 4 (ANI): Spanish Oncology has established a new standard treatment for breast cancer at early stages, thanks to the results of a new study.
The results have suggested that docentaxel during quimotherapy reduces the risk of recurrence by 32 percent in women with high-risk but node-negative, early stage breast cancer when cancer has not spread to lymph nodes.
The aim of the research was to test the efficiency between a drug combination of docetaxel and cyclophosphamide (TAC) in comparision with the traditional treatment of fluorouracil, doxorubicin and cyclophosphamide (FAC).
1060 women participating in the study were randomly assigned to receive TAC or FAC after surgery treated. They received treatment one day every three weeks during six cycles.
Scientifics evaluated those criteria: disease-free survival, global survival, treatment security levels and life quality.
The results after six years have shown that adjuvant therapy based on TAC reduce risk of recurrence by 32 percent and improve disease-free survival. Almost 90 percent remained disease-free after this period.
“It is a step towards personalized treatments of this tumour, since the goal is to administrate just those therapies aimed at caused a benefit, avoiding secondary effects,” said Miguel Martin of Gregorio Maranon Hospital, Madrid.
The findings were published in the New England Journal of Medicine. (ANI)
- Women treated for breast cancer while pregnant have improved survival - Sep 30, 2010
- Lymph node removal 'not always needed in early-stage breast cancer' - Feb 09, 2011
- Chemo plus tamoxifen beneficial for some breast cancer patients - Dec 11, 2009
- Circulating tumour cells in blood up death risk in early-stage breast cancer patients - Dec 11, 2010
- Radiation ineffective after mastectomy, says study - Mar 07, 2010
- Breast cancer survivors are at higher risk for hip fractures - Feb 03, 2011
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- Chemo drugs may lead to cognitive decline - Dec 18, 2009
- Breast cancer survivors with physical limitations more likely to die - Sep 25, 2010
- Novel imaging technique may cut lymphedema in breast cancer patients - Dec 12, 2010
- Multivitamin has no effect on colon cancer outcomes - Sep 08, 2010
- Bone drug may help fight breast cancer - Jun 03, 2010
- Alcohol intake after breast cancer diagnosis may increase recurrence risk - Sep 16, 2010
- Taking tamoxifen to prevent breast cancer can save lives and cut medical costs - Mar 14, 2011
Tags: breast cancer, docetaxel, doxorubicin, drug combination, england journal of medicine, free survival, global survival, gregorio maranon hospital, high risk, hospital madrid, journal of medicine, life quality, lymph nodes, new england journal, new england journal of medicine, quimotherapy, recurrence, security levels, stage breast cancer, tumour